Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells 176,647 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 176,647 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $7.21, for a total transaction of $1,273,624.87. Following the completion of the sale, the insider now owns 2,876,027 shares in the company, valued at approximately $20,736,154.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.05, for a total transaction of $80,500.00.
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total transaction of $207,718.00.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) traded down 13.11% during trading on Friday, reaching $6.96. 162,624 shares of the company’s stock were exchanged. The company’s market capitalization is $67.60 million. KalVista Pharmaceuticals, Inc. has a 12-month low of $6.09 and a 12-month high of $10.65. The stock has a 50-day moving average price of $8.20 and a 200 day moving average price of $7.83.
KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The company had revenue of $0.10 million for the quarter. KalVista Pharmaceuticals had a negative return on equity of 63.41% and a negative net margin of 5,863.31%. Equities analysts expect that KalVista Pharmaceuticals, Inc. will post ($2.94) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells 176,647 Shares of Stock” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/insider-selling-kalvista-pharmaceuticals-inc-kalv-major-shareholder-sells-176647-shares-of-stock.html.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned approximately 1.01% of KalVista Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 75.66% of the company’s stock.
Several research analysts have commented on KALV shares. ValuEngine raised shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 2nd. BTIG Research began coverage on shares of KalVista Pharmaceuticals in a research note on Thursday, August 31st. They set a “buy” rating and a $18.00 target price for the company.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.